NCT03547622View on ClinicalTrials.gov

Galantamine and CBT4CBT Pilot to Prevent Relapse.

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

February 28, 2019

Study Completion Date

February 28, 2019

Conditions
Methadone or Buprenorphine Detoxoxification
Interventions
DRUG

MAT taper with galantamine

Following taper from MAT (methadone or buprenorphine) participants will be given galantamine daily with access to a CBT4CBT computer program

DRUG

MAT taper with placebo

Following taper from MAT (methadone or buprenorphine) participants will be given placebo daily with access to a CBT4CBT computer program

Trial Locations (1)

06511

APT Foundation, New Haven

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Yale University

OTHER

NCT03547622 - Galantamine and CBT4CBT Pilot to Prevent Relapse. | Biotech Hunter | Biotech Hunter